Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Allergies and COVID-19 vaccines : an ENDA/EAACI position paper
Avtorji:ID Barbaud, Annick (Avtor)
ID Garvey, Lene Heise (Avtor)
ID Arcolaci, Alessandra (Avtor)
ID Brockow, Knut (Avtor)
ID Mori, Francesca (Avtor)
ID Mayorga, Cristobalina (Avtor)
ID Jošt, Maja, Klinika Golnik (Avtor)
ID Košnik, Mitja, Klinika Golnik, Medicinska fakulteta UL (Avtor)
ID Zidarn, Mihaela, Klinika Golnik, Medicinska fakulteta UL (Avtor)
ID Torres, Maria J (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.15241
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Anaphylaxis, which is rare, has been reported after COVID 19 vaccination, but its management is not standardized. Method. Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed. Results. No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine, are excipients. The authors propose allergy evaluation of persons with the following histories: 1- anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2- anaphylaxis to oral/topical PEG containing products; 3-recurrent anaphylaxis of unknown cause; 4-suspected or confirmed allergy to any mRNA vaccine, 5-confirmed allergy to PEG or derivatives. We recommend a prick-to-prick skin test with the left over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable. Conclusions. These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID-19 vaccines and enable more people with history of allergy to be vaccinated.
Ključne besede:SARS-CoV-2, COVID-19, COVID-19 vaccines, allergens, anapylaxis, drug hypersensitivity
Status publikacije:V tisku
Verzija publikacije:Recenzirani rokopis
Kraj izida:VelikaBritanija
Založnik:Wiley
Leto izida:2022
Št. strani:str. [1-58]
Številčenje:Vol. 77, iss.
PID:20.500.12556/DiRROS-14740 Novo okno
UDK:616-097
ISSN pri članku:1398-9995
DOI:10.1111/all.15241 Novo okno
COBISS.SI-ID:96566531 Novo okno
Opomba:Nasl. z nasl. zaslona; Soavtorji iz Slovenije: Maja Jošt, Mitja Košnik, Mihaela Zidarn; Opis vira z dne 7. 2. 2022;
Datum objave v DiRROS:07.02.2022
Število ogledov:777
Število prenosov:242
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Allergy
Založnik:Blackwell
ISSN:1398-9995
COBISS.SI-ID:515009305 Novo okno

Sekundarni jezik

Jezik:Ni določen
Ključne besede:SARS-CoV-2, covid-19, cepiva proti covidu-19, alergeni, anafilaksija, preobčutljivost za zdravila


Nazaj